Skip to main content
. 2016 Aug 4;7(36):58696–58708. doi: 10.18632/oncotarget.11061

Figure 1.

Figure 1

Histomorphologic appearance of a retroperitoneal tumor that could not be accurately classified by pathologists despite extensive work-up and opinions of multiple nationally-recognized experts (A. H&E, x100). The tumor responded to treatment with temsirolimus and an immunohistochemical stain revealed immunoreactivity with phosphorylated mTOR antibody test (B. x200).

HHS Vulnerability Disclosure